Segasist Technologies, a MaRS Discovery District Client, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Prostate Auto-Contouring software 'Segasist P-AC'.
The week of October 3, 2011, Segasist Technologies, a MaRS client and tenant will launch its' new cancer diagnostic tool Reconcillio at the American Society for Radiation Oncology conference. Reconcillio is Segasist Technologies' third product and is awaiting FDA approvals.
Segasist Technology has developed special software for doctors to help read medical images. Jaqueline Csonka-Peeren, president and CEO, Segasist Technology tells BNN more. Nov 6, 2009
MaRS life sciences and health care practice client, Dr. Hamid Tizhoosh, founder of Segasist, is interviewed for CityNews. He talks about how he became and entrepreneur and how this shapes his life.